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Facultative liver stem cells have long been thought to be an important source of new hepatocytes during
chronic liver injury. This longstanding paradigm is being challenged by two papers discussed herein (Schaub
et al., 2014; Yanger et al., 2014).The liver has been renowned for its
remarkable regenerative capacity since
antiquity. Large portions of the liver can
be removed surgically multiple times
(Miyajima et al., 2014) and the organ will
grow back to its original size each time
in a process reminiscent of limb regenera-
tion in amphibians. Mature hepatocytes
have stem-cell-like self-renewal capacity
as shown by serial transplantation. How-
ever, the field has long held that liver
regeneration can be driven not only by he-
patocytes but also by facultative stem
cells under certain injury conditions (Miya-
jima et al., 2014). But now, using comple-
mentary lineage tracing approaches,
Yanger et al. (2014) (in this issue of Cell
Stem Cell) and Schaub et al. (2014) (Cell
Reports) find no evidence for liver stem
cells participating in liver regeneration.
The concept of liver stem cells emerged
originally from studies in the rat where the
combination of DNA damage and partial
hepatectomy results in the emergence
of ‘‘oval cells’’ from the biliary tree. Rat
oval cells are positive for alpha-fetopro-
tein (AFP), a marker of fetal hepatoblasts,
and express markers of both the biliary
and hepatocyte lineages. Classic lineage
tracing studies using tritiated thymidine
to mark replicating cells and follow their
fate indicated that these oval cells could
give rise to hepatocytes (Evarts et al.,
1987) and in some scenarios even to in-
testinal epithelium. The inability of mat-
ure hepatocytes to divide is a common
feature of all injury regiments capable of
producing the oval cell response in rats.
These observations gave rise to a para-
digm wherein hepatocyte senescence in
the face of injury would activate the facul-
tative hepatic stem/progenitor cell. This
concept fit with clinical observations in
chronic human liver disease, character-
ized by hepatocyte senescence, ductularproliferation, and the emergence of cells
bearing characteristics of both biliary
duct cells and hepatocytes. However,
the source of these biphenotypic, oval-
like cells was debated from early on
(Farber, 1956), with one school of thought
being that they represented stem cells on
their way to becoming hepatocytes. The
opposing model held that the cells were
derived from dedifferentiated hepato-
cytes. Eventually, the stem cell view pre-
vailed and much effort went into isolating
and characterizing liver stem/progenitor
cells (LSPCs).
The mouse quickly became the organ-
ism of choice for LSPC research because
of the availability of genetic tools. The
classic regimens of oval cell induction
in the rat do not elicit the equivalent
response in the mouse, which prompted
development of multiple new protocols
to induce ductular proliferation and oval
cell injury in mice. Importantly, classic
FACS separation methods were used to
isolate a subset of clonogenic biliary cells
that could be expanded and differentiated
into either bile ducts or hepatocytes
in vitro (Dorrell et al., 2011). In addition,
these cells were able to produce bona
fide hepatocytes upon transplantation
(Huch et al., 2013). Similarly, recent in vivo
lineage tracing studies using inducible
cre-recombinase indicated that biliary
cells could be the precursors to hepato-
cytes during oval cell injury and even dur-
ing normal liver homeostasis (Furuyama
et al., 2011). Thus, these and many other
studies were completely consistent with
the notion of a facultative LSPC that
would be called upon to produce hepato-
cytes during certain chronic injuries.
Multiple studies from different labora-
tories are now, however, finding no evi-
dence of the existence of LSPCs in adult
mice. The laboratory of Ben StangerCell Stem Cell 15, S(Yanger et al., 2014) used three distinct
approaches to determine whether cells
other than hepatocytes themselves could
be the source of new hepatocytes in oval
cell injury. They used all four classic
mouse oval cell injury regimens including
DDC-induced damage, the CDE diet,
and chronic CCl4 and ANIT. The first
approach used a bile-duct-specific, ta-
moxiphen-inducible cre-line (CK19) and
failed to demonstrate any CK19-marked
hepatocytes in any injury model. The sec-
ond method involved high-efficiency la-
beling of mature hepatocytes followed
by oval cell injury and subsequent quanti-
tation of unlabeled hepatocytes. Again,
there was no evidence for the existence
of a nonhepatocyte LSPC. Finally, they
used nucleoside analogs to label any
rapidly dividing cells during oval cell injury
and trace their fate. This approach argued
against the rapidly proliferating oval cell
being a hepatocyte precursor. The group
of Holger Willenbring (Schaub et al.,
2014) focused specifically on the CDE
diet and also used multiple approaches
to determine whether LSPCs could be
found in vivo. CK19 lineage tracing and
high-efficiency hepatocyte marking pro-
duced results very similar to those of
Yanger et al., i.e., they produced no evi-
dence for a hepatocyte stem cell. In addi-
tion, they performed fate tracing using
Pdgfrb-cre, a marker for stellate cells/my-
ofibroblasts that have been reported to be
hepatocyte precursors. Their results
definitively ruled out this lineage as that
of an LSPC.
In addition to these two studies, lineage
tracing studies in murine oval cell injury
have been done recently with the biliary
markers Sox9 (Tarlow et al., 2014) and
Hnf1b (Rodrigo-Torres et al., 2014). Over-
all, all four studies (Rodrigo-Torres et al.,
2014; Schaub et al., 2014; Tarlow et al.,eptember 4, 2014 ª2014 Elsevier Inc. 257
Figure 1. Summary of the Evidence against Murine LSPCs as Hepatocyte Precursors
The different methods (red font color) to exclude nonhepatocyte LSPCs as a source of hepatocytes in oval
cell injury include nucleoside labeling of rapidly dividing cells (Yanger et al., 2014); lineage tracing of biliary
cells with CK19 (Schaub et al., 2014; Yanger et al., 2014), Sox9 (Tarlow et al., 2014), and Hnf1b (Rodrigo-
Torres et al., 2014); and lineage tracing of stellate/fibroblastic cells with Pdfgrb (Schaub et al., 2014).
Evidence for hepatocytes themselves (green font color) being the only source of new parenchymal cells
includes their being marked with hepatocyte-specific rAAVs (Schaub et al., 2014; Yanger et al., 2014)
and chimeras in the Fah mouse (Tarlow et al., 2014).
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Previews2014; Yanger et al., 2014) argue strongly
against LSPCs as a significant source of
new hepatocytes in the mouse and call
the very concept of an adult liver stem
cell into question (Figure 1). Conversely,
it is clear that adult hepatocytes can repli-
cate even with very severe liver damage,
obviating the very need for a stem cell.
Despite this apparent change in para-
digm it is important to moderate the
generalization of these findings. First, all258 Cell Stem Cell 15, September 4, 2014 ª2studies to date have been limited to the
mouse and it is premature to conclude
that LSPCs do not exist in anymammalian
species. Curiously, none of the oval cell
injury regimens in the mouse result in the
emergence of AFP-positive cells. This rai-
ses the question of whether the proper
injury regimen for oval cell activation
capable of revealing the LSPC in mice re-
mains to be identified. Similarly, conclu-
sive data on LSPCs in human liver do014 Elsevier Inc.not yet exist. Second, it should be empha-
sized that clonogenic liver cells capable of
in vitro expansion and hepatocytic differ-
entiation clearly can be found in multiple
species. While these cells may not repre-
sent an important source of regeneration
in vivo, their expandability and hepa-
tocytic potential still make them an at-
tractive potential source of liver cells for
regenerative medicine.
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